Mechanisms of acquired in vivo and in vitro resistance to voriconazole by Candida krusei following exposure to suboptimal drug concentration

Elisabete Ricardo*, Fréderic Grenouillet, Isabel M. Miranda, Raquel M. Silva, Guilluame Eglin, Nadège Devillard, Acácio Gonçalves Rodrigues, Cidália Pina-Vaza

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

8 Citações (Scopus)

Resumo

Five Candida krusei isolates (susceptible and resistant) recovered from the urine of a kidney transplant patient treated with voriconazole (VRC) 200 mg twice daily for 20 days were studied. Eight unrelated clinical isolates of C. krusei were exposed in vitro to VRC 0.001 μg/ml for 30 days. Development of VRC transient resistance occurred in vivo, and induction of permanent resistance occurred in vitro. Mostly, ABC1 and ERG11 genes were overexpressed, and a homozygous T418C mutation in the ERG11 gene was found.
Idioma originalEnglish
Número do artigoe01651-19
Número de páginas6
RevistaAntimicrobial Agents and Chemotherapy
Volume64
Número de emissão4
DOIs
Estado da publicaçãoPublicado - 2020

Impressão digital

Mergulhe nos tópicos de investigação de “Mechanisms of acquired in vivo and in vitro resistance to voriconazole by Candida krusei following exposure to suboptimal drug concentration“. Em conjunto formam uma impressão digital única.

Citação